Current options in the treatment of non-small cell lung cancer.

Abstract:

:Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in industrialised countries, with an overall 5-year survival rate of less than 10%. Good patient performance status is associated with a significantly improved prognosis, whereas the presence of metastases, particularly to the bone or liver, is associated with a poor outcome. Disease staging has largely been standardised using the tumour, node, metastasis (TNM) system, and also provides significant prognostic information. More recently, several biomarkers have been identified in patients with NSCLC, although their prognostic relevance remains to be established. Surgery, when feasible, is the treatment of choice in patients with NSCLC. However, most patients present with locally advanced disease that is not completely resectable. The use of combination chemotherapy regimens has generally been restricted to patients with metastatic, recurrent or unresectable disease, and several relatively active drugs that are generally used in combination have been identified. Combination chemotherapy either alone, or with surgery and/or radiotherapy, has produced some improvements in response rates and, in the neoadjuvant setting, has allowed complete resection in an increased number of patients with otherwise marginally resectable disease. There is also evidence that this approach may increase both disease-free interval and survival time. Thus, the most active chemotherapy regimens (generally those including cisplatin and a vinca alkaloid) appear to provide some benefit in patients with advanced non-small cell lung cancer, but the identification of more active combinations remains a priority.

journal_name

Drugs

journal_title

Drugs

authors

Faulds D

doi

10.2165/00003495-199200444-00006

subject

Has Abstract

pub_date

1992-01-01 00:00:00

pages

46-59

eissn

0012-6667

issn

1179-1950

journal_volume

44 Suppl 4

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Acute viral infections of the central nervous system in immunocompetent adults: diagnosis and management.

    abstract::Patients with viral infections of the central nervous system (CNS) may present with a variety of neurological symptoms, most commonly dominated by either encephalitis or meningitis. The aetiological panorama varies in different parts of the world as well as over time. Thus, virological first-line diagnostics must be a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0007-5

    authors: Studahl M,Lindquist L,Eriksson BM,Günther G,Bengner M,Franzen-Röhl E,Fohlman J,Bergström T,Aurelius E

    更新日期:2013-02-01 00:00:00

  • Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.

    abstract::Gemfibrozil improves lipid and apolipoprotein profiles, particularly very low density lipoprotein (VLDL) triglyceride and high density lipoprotein (HDL) cholesterol levels, in patients with dyslipidaemia when administered at a total daily dose of 900 or 1200 mg. As demonstrated by the Helsinki Heart Study, these effec...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199651060-00009

    authors: Spencer CM,Barradell LB

    更新日期:1996-06-01 00:00:00

  • Acitretin : A Review of its Pharmacology and Therapeutic Use.

    abstract:SYNOPSIS:Acitretin (etretin), a second generation monoaromatic retinoid for use in the treatment of severe psoriasis and other dermatoses, is the major active metabolite of etretinate and possesses a similar therapeutic index; i.e. a similar ratio of clinical efficacy to adverse effects. When used alone at a maintenanc...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-199243040-00010

    authors: Pilkington T,Brogden RN

    更新日期:1992-04-01 00:00:00

  • Potassium channel openers in myocardial ischaemia: therapeutic potential of nicorandil.

    abstract::Potassium channel openers or agonists represent a novel new class of compounds in the treatment of a range of cardiovascular disorders, particularly angina pectoris and hypertension. Nicorandil is the only clinically available potassium channel opener with antianginal effects, and with comparable efficacy and tolerabi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161120-00002

    authors: Gomma AH,Purcell HJ,Fox KM

    更新日期:2001-01-01 00:00:00

  • Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

    abstract::Alteplase is the product of recombinant DNA technology and is chemically identical to endogenous tissue-type plasminogen activator: Plasminogen is converted to plasmin by alteplase, and fibrinolysis of blood thrombi is subsequently stimulated. Alteplase is now firmly established as a treatment of choice in the managem...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199550020-00007

    authors: Wagstaff AJ,Gillis JC,Goa KL

    更新日期:1995-08-01 00:00:00

  • Epidemiology and therapy of Chlamydia trachomatis infections.

    abstract::Chlamydia trachomatis infections are exceedingly prevalent, and can be associated with significant sequelae. The major infections are urethritis, cervicitis, salpingitis, and ocular infection. Chlamydial genital infections present as syndromes, where C. trachomatis is one of the causes of the syndrome. Because specifi...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198427050-00005

    authors: Bowie WR

    更新日期:1984-05-01 00:00:00

  • Valsartan/hydrochlorothiazide.

    abstract::Valsartan/hydrochlorothiazide (HCTZ) combines an angiotensin II AT1 receptor blocker with a thiazide diuretic to produce additive blood pressure reductions without major effects on heart rate. HCTZ did not significantly alter valsartan pharmacokinetics; during combination therapy, HCTZ pharmacokinetics differed from t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957050-00008

    authors: Langtry HD,McClellan KJ

    更新日期:1999-05-01 00:00:00

  • Pharmacotherapy for hepatic encephalopathy.

    abstract::Hepatic encephalopathy (HE) is a challenging clinical complication of liver dysfunction with a wide spectrum of neuropsychiatric abnormalities that range from mild disturbances in cognitive function and consciousness to coma and death. The pathogenesis of HE in cirrhosis is complex and multifactorial, but a key role i...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/10898630-000000000-00000

    authors: Phongsamran PV,Kim JW,Cupo Abbott J,Rosenblatt A

    更新日期:2010-06-18 00:00:00

  • Uraemic pruritus: clinical characteristics, pathophysiology and treatment.

    abstract::Pruritus is a common complication of end-stage renal disease (ESRD), affecting about one-third of dialysis patients. It is a chronic, unpleasant symptom with a strong negative impact on patients' quality of life, often inducing sleeplessness and mood disorders. Recent data show that it is also associated with increase...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969030-00002

    authors: Manenti L,Tansinda P,Vaglio A

    更新日期:2009-01-01 00:00:00

  • Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.

    abstract::Cilazapril is an orally active angiotensin converting enzyme (ACE) inhibitor which lowers peripheral vascular resistance without affecting heart rate. Like enalapril and ramipril it is a prodrug, and is hydrolysed after absorption to cilazaprilat, which has a long terminal phase elimination half-life permitting once d...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199141050-00008

    authors: Deget F,Brogden RN

    更新日期:1991-05-01 00:00:00

  • The memory clinic. A new approach to the detection of early dementia.

    abstract::Dementia is commonly diagnosed at a time of major domestic breakdown, when symptoms are severe and family and community patience has been eroded. In order to encourage early referral and identification of patients with treatable conditions, a Memory Clinic is held at the University Hospital in Cardiff. The clinic prov...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198700332-00016

    authors: Bayer AJ,Pathy MS,Twining C

    更新日期:1987-01-01 00:00:00

  • Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations.

    abstract::Platinum-based doublet chemotherapy with or without bevacizumab is the standard of care for the initial management of advanced and metastatic non-small cell lung cancer (NSCLC) without a targetable molecular abnormality. However, the majority of patients with NSCLC will ultimately develop resistance to initial platinu...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0628-6

    authors: Barnfield PC,Ellis PM

    更新日期:2016-09-01 00:00:00

  • Diuretic-induced magnesium losses.

    abstract::Long term administration of common loop or distal tubular diuretics may cause somatic magnesium depletion. The resultant deficiency of Mg++ destabilises the myocardium electrically and is a principal cause of cardiac arrhythmias ascribed to diuretics. The adverse effects of diuretics caused by Mg++ depletion can be av...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198400281-00018

    authors: Leary WP,Reyes AJ

    更新日期:1984-10-01 00:00:00

  • Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function.

    abstract::Because of inappropriate signals from the volume-regulation system and a reduction in renal blood flow, the kidney is not able to prevent sodium and water retention in chronic congestive heart failure (CHF). A brief summary of normal renal function and renal involvement in CHF is given and a study of renal function in...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-199000394-00004

    authors: Ljungman S,Laragh JH,Cody RJ

    更新日期:1990-01-01 00:00:00

  • Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies.

    abstract::In recent years, there have been major advances in the management of rheumatoid arthritis (RA), leading to the development of tumour necrosis factor (TNF) antagonists. With these agents, it is possible to arrest joint damage and, by treating early in the disease course, to prevent joint damage. It is also now thought ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666140-00001

    authors: Montecucco C

    更新日期:2006-01-01 00:00:00

  • An evaluation of eptacog alfa in nonhaemophiliac conditions.

    abstract::We have analysed the published literature on eptacog alfa (recombinant factor VIIa; rFVIIa) for nonhaemophiliac conditions with the aim of determining its current place in therapy. Initial surgical and/or medical management is required for any patient with life-threatening bleeding. In those with continued life-threat...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868120-00005

    authors: Mallarkey G,Brighton T,Thomson A,Kaye K,Seale P,Gazarian M

    更新日期:2008-01-01 00:00:00

  • Correction to: Isatuximab: First Approval.

    abstract::In the table 'Key clinical trials of isatuximab (Sanofi)', in the left-hand column. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-020-01325-9

    authors: Dhillon S

    更新日期:2020-06-01 00:00:00

  • Current concepts in diabetic gastroparesis.

    abstract::Diabetic gastroparesis is a common and debilitating condition affecting millions of patients with diabetes mellitus worldwide. Although gastroparesis in diabetes has been known clinically for more than 50 years, treatment options remain very limited. Until recently, the scientific literature has offered few clues rega...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363130-00002

    authors: Smith DS,Ferris CD

    更新日期:2003-01-01 00:00:00

  • Clinical potential of topical corticosteroids.

    abstract::The treatment of a variety of inflammatory skin diseases was greatly changed by the introduction, in the early 1950s, of corticosteroids for topical use. Topical corticosteroids are still the most widely used drugs in dermatology, and many preparations with quite different potencies are now available. However, attempt...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800365-00008

    authors: Ortonne JP

    更新日期:1988-01-01 00:00:00

  • Value of non-drug treatment and drug treatment in hypertension.

    abstract::The benefits of the treatment of hypertension currently consist of a substantially reduced incidence of premature stroke, left ventricular failure and malignant hypertension. The benefits for the individual are most clearcut in those who have already had severe or symptomatic hypertension. Older subjects who have a hi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800366-00003

    authors: Beilin LJ

    更新日期:1988-01-01 00:00:00

  • Clascoterone: First Approval.

    abstract::Clascoterone (Winlevi®) is an androgen receptor inhibitor being developed as a topical cream and solution by Cassiopea (a spin-out company of Cosmo Pharmaceuticals) for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. Although the exact mechanism of action of clasc...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01417-6

    authors: Dhillon S

    更新日期:2020-11-01 00:00:00

  • Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.

    abstract::Cefixime is an orally active third generation cephalosporin with in vitro antibacterial activity against most important lower respiratory pathogens. The drug is active against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus pneumoniae but not Staphylococcus aureus. Cefixime has a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549060-00010

    authors: Markham A,Brogden RN

    更新日期:1995-06-01 00:00:00

  • Pharmacotherapeutic management of locally advanced prostate cancer: current status.

    abstract::Locally advanced prostate cancer (LAPC) is a heterogeneous entity usually embracing T3-4 and/or pelvic lymph-node-positive disease in the absence of established metastases. Outcomes for LAPC with single therapies have traditionally been poor, leading to the investigation of adjuvant therapies. Prostate cancer is a hor...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11591500-000000000-00000

    authors: Martin JM,Supiot S,Berthold DR

    更新日期:2011-05-28 00:00:00

  • Histamine and leukotriene receptor antagonism in the treatment of allergic rhinitis: an update.

    abstract::Allergic rhinitis represents a global health burden. The disease can seriously affect quality of life and is associated with multiple co-morbidities. Histamine and leukotrienes are important pro-inflammatory mediators in nasal allergic inflammation. Their actions on target cells are mediated through specific receptors...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767180-00006

    authors: Van Hoecke H,Vandenbulcke L,Van Cauwenberge P

    更新日期:2007-01-01 00:00:00

  • Catecholamines: role in health and disease.

    abstract::The naturally occurring catecholamines, noradrenaline, adrenaline and dopamine, have been found in a wide range of animal and vegetable tissues, but are particularly associated with nervous tissue in animals. Of the many processes affecting the response to stimulation of catecholamine containing nerves, the synthesis ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197816050-00003

    authors: Laverty R

    更新日期:1978-11-01 00:00:00

  • Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke.

    abstract::Stroke is the third most common cause of death in the US. Primary prevention of stroke can be achieved by control of risk factors including hypertension, diabetes mellitus, elevated cholesterol levels and smoking. Approximately one-third of all ischaemic strokes occur in patients with a history of stroke or transient ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565040-00003

    authors: Weinberger J

    更新日期:2005-01-01 00:00:00

  • Gatifloxacin: a review of its use in the management of bacterial infections.

    abstract:UNLABELLED:Gatifloxacin is an 8-methoxy fluoroquinolone antibacterial agent. The drug has a broader spectrum of antibacterial activity than the older fluoroquinolones (e.g. ciprofloxacin) and shows good activity against many Gram-positive and Gram-negative pathogens, atypical organisms and some anaerobes. Notably, gati...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262010-00007

    authors: Perry CM,Ormrod D,Hurst M,Onrust SV

    更新日期:2002-01-01 00:00:00

  • Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.

    abstract:UNLABELLED:Oxaliplatin is a platinum compound that inhibits DNA synthesis, primarily by causing intrastrand cross-links in DNA. Oxaliplatin has a broad spectrum of antineoplastic activity and has demonstrated a lack of cross-resistance with other platinum compounds. In patients with metastatic colorectal cancer, intrav...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060040-00005

    authors: Culy CR,Clemett D,Wiseman LR

    更新日期:2000-10-01 00:00:00

  • Antiplatelet drugs: clinical pharmacology and therapeutic use.

    abstract::Because platelets are so important in thrombus formation, drugs which inhibit platelet function (the 'antiplatelet drugs') have considerable potential as antithrombotic agents. Among the antiplatelet drugs, only aspirin, sulphinpyrazone, dipyridamole, hydroxychloroquine, and clofibrate have had wide clinical trial. Th...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197918060-00002

    authors: Gallus AS

    更新日期:1979-12-01 00:00:00

  • HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk.

    abstract::HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure w...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666020-00002

    authors: Laufs U,Custodis F,Böhm M

    更新日期:2006-01-01 00:00:00